leadf
logo-loader
viewEQTEC PLC

EQTEC says US patent claim is opportunistic and will be defended vigorously

The complaint is specific to the US only and does not extend to the company's activities and pipeline of projects in the UK and Europe

EQTEC PLC -
Claim has been filed in a court in California

EQTEC PLC (LON:EQT) has said it will vigorously defend a claim of patent infringement filed against it in the US, adding it was opportunistic and spurious.

Aries Clean Energy of Franklin, Tennessee, filed the complaint on July 9, 2020, alleging the infringement in the use of EQTEC’s advanced gasification technology in the North Fork Community Power plant in California.  

The complaint is specific to the US only and does not extend to the company's activities and pipeline of projects in the UK and Europe, EQTEC said in a statement. 

The AIM-listed firm added that it believes the Aries claim as filed is without merit and refuted any allegation that the group’s technology infringes any valid US patent

EQTEC said its technological pre-eminence in the gasification of waste into energy market might make it subject to spurious and unfounded potential claims in relation to patent protection from time to time.

The claim was filed on the same day last week that it completed a £10mln fundraise, noted EQTEC, adding further to its view that it is an opportunistic move.

Quick facts: EQTEC PLC

Price: 0.75 GBX

AIM:EQT
Market: AIM
Market Cap: £51.52 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of EQTEC PLC named herein, including the promotion by the Company of EQTEC PLC in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Market Report: FTSE jumps on AstraZeneca COVID-19 vaccine trial and easing...

FTSE 100 rallied in early trading on AstraZeneca’s COVID-19 vaccine trial and the easing of lockdown restrictions from December. London’s blue-chip index rose 20 to 6,371. AstraZeneca PLC (LON:AZN) announced that the coronavirus (COVID-19) vaccine it has developed with Oxford University was...

5 days, 21 hours ago

2 min read